Pulse Biosciences Q1 2025: Revenue Flat, Expenses High
Ticker: PLSE · Form: 10-Q · Filed: May 8, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: 10-Q, biotech, financials, operating-expenses
TL;DR
Pulse Biosciences Q1 2025: $0 revenue, $6M in expenses. Still burning cash.
AI Summary
Pulse Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $0.001 in revenue for the first quarter of 2025, with total assets valued at $67,274. Operating expenses were $6,000,000, leading to a net loss for the period. The company is focused on its clinical stage devices.
Why It Matters
This filing provides insight into Pulse Biosciences' financial health and operational spending as it advances its clinical stage medical devices.
Risk Assessment
Risk Level: high — The company has minimal revenue and significant operating expenses, indicating a high burn rate and reliance on future funding or product success.
Key Numbers
- $0.001 — Revenue (Q1 2025 revenue was negligible.)
- $6,000,000 — Operating Expenses (Significant expenses incurred during the period.)
- $67,274 — Total Assets (Low asset base as of March 31, 2025.)
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- $6,000,000 (dollar_amount) — Operating expenses for the period
- $67,274 (dollar_amount) — Total assets at the end of the period
- $0.001 (dollar_amount) — Revenue for the first quarter of 2025
FAQ
What is the company's revenue for the first quarter of 2025?
The company reported $0.001 in revenue for the first quarter of 2025.
What were the total operating expenses for the period ending March 31, 2025?
Total operating expenses were $6,000,000.
What is the total asset value reported in the 10-Q?
The total assets reported as of March 31, 2025, were $67,274.
What is the primary business focus of Pulse Biosciences?
The company is focused on its clinical stage devices, with manufacturing costs including compensation, consultant fees, and materials for these devices.
What does 'Other segment items' include?
Other segment items include stock-based compensation, depreciation and amortization, and allocations of facilities and IT costs.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding PULSE BIOSCIENCES, INC. (PLSE).